InsidersTradesSigma
Track the Cellular Biomedicine Group, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was disclosed on 21 January 2016 (Levée d'options). Among the most active insiders: Chan Andrew K. All data is openly available.
Analysts rate Cellular Biomedicine Group, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
4 of 4 declarations
Cellular Biomedicine Group, Inc. is a company focused on developing cell therapies for the treatment of serious diseases. It is listed on NASDAQ under the symbol CBMG.